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Edited by Richard MaraisAbstract Increasing evidence suggests that lysosomal cysteine
proteases cathepsins contribute to the progression of cell apopto-
sis. Here we found that apoptosis of ovarian cancer cells OV-90
triggered by TNF was cathepsin B-depended. Two cathepsin B
binding proteins, bikunin and TSRC1, were identiﬁed by yeast
two-hybrid method and the interactions were conﬁrmed in vitro
and in vivo. Overexpression of bikunin could suppress TNF-in-
duced apoptosis of OV-90 cells, and TSRC1 overexpression
had an opposite eﬀect on apoptosis. The presented results suggest
that cathepsin B and its interacting proteins, bikunin and
TSRC1, are involved in the apoptotic pathway of ovarian cancer
cells.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Apoptosis is an active form of cell death by which multicel-
lular organisms eliminate damaged or otherwise unwanted
cells. The apoptosis process is controlled by a number of com-
plex proteins which are activated by various triggers and ar-
ranged in sequential signaling modules. Apoptosis can be
initiated either through death receptors on the cell surface,
an extrinsic pathway or through mitochondria, an intrinsic
pathway. Both pathways converge to a ﬁnal common pathway
involved in the activation of a cascade of caspases. The acti-
vated executioner caspases cleave key regulatory and structural
molecules, culminating in cell death [1].
Tumor necrosis factor (TNF) is a pleiotropic cytokine capa-
ble of eliciting complex and diverse cellular events, including
apoptosis, cell growth and proinﬂammatory genes expression
[1,2]. TNF triggers cell apoptosis by binding to TNF receptor1
(TNFR1). Binding of TNF leads to the trimerization of
TNFR1 and subsequent recruitment of TNFR1-associated
death domain protein (TRADD), TNF receptor associated
factor 2 (TRAF2), and the death domain kinase RIP. These
proteins form a plasma membrane bound complex (complex
1). After dissociation from TNFR1, complex 1 components
TRADD, TRAF2 and RIP associate with Fas associated
death domain protein (FADD) and caspase-8, forming a cyto-*Corresponding author. Fax: +86 21 65643436.
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in complex 2, followed by the activation of downstream execu-
tioner caspases and ﬁnal cell death.
TNF can concomitantly induce the gene expression that pro-
mote cell survival through the TNF receptor complex associat-
ing proteins TRAF2 and RIP1, which activate NF-jB and
MAPKs signaling cascades. The speciﬁc consequences of
TNF signaling depend on the cell type and context. Some cells
can be susceptible to TNF cytotoxicity by selective blockade of
the NF-jB pathway or by general inhibition of transcription
or translation [2,3].
It is a general goal to seek factors to control apoptosis and
to understand functions of the factors in the apoptosis. Based
on existing data, caspases are well recognized as a key player
and other proteases such as cathepsins, calpains, and serine
proteases may account for alternative types of apoptosis [4].
Cathepsins, a family of cysteine proteases, are normally local-
ized in lysosomes serving as simple housekeeper enzymes in-
volved in intracellular protein catabolism [5]. Recently, it is
found that the leakage of lysosomal cathepsins into cytosol
caused by some agents or stimuli can result in apoptosis of
some cells [6–8]. For example, p53 in M1 mouse myeloid leu-
kemic cells induces apoptosis and this type of apoptosis is ini-
tiated by lysosomal destabilization [7]. Moreover, some
microtubule stabilizing agents such as paclitaxel induce cell
death in non-small cell lung cancer cells, and this type of cell
death is not depended on caspases while caused by disruption
of lysosomes and release and activation of cathepsin B [8].
Cathepsin B is the most abundant cysteine protease in lyso-
somes, and based on recent reports, it is involved in apopto-
sis [6,9–11]. The typical studies in the cathepsin B-knockout
mice have recognized the cathepsin B as a potent inducer
of apoptosis [9]. At the same time, there exist diﬀerent reports
regarding mechanisms for role of cathepsin B in the apopto-
sis. When some cells are treated by TNF, cathepsin B re-
leased from ruptured lysosomes into cytosol activates
caspase-dependent or caspase-independent pathways of cell
death [10–12].
The mechanisms of apoptosis mediated by lysosomal cathep-
sins remain to be elucidated in most cases. In order to under-
stand factors involved in the cathepsin B-mediated death
pathway, we used the yeast two-hybrid system to hunt for
cathepsin B binding proteins. Bikunin and TSRC1 (Gene Bank
Accession No. BC027478) were identiﬁed and conﬁrmed to
interact with cathepsin B in vivo and in vitro. Bikunin is a mem-
ber of the kunitz-type protease family and acts as an inhibitor
against trypsin, plasmin and leukocyte elactase [13], whereas
the function of TSRC1 remains unknown. In the presentedation of European Biochemical Societies.
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duce apoptosis of ovarian cancer cells OV-90 and this process
is cathepsin B-depended. Overexpression of bikunin suppresses
TNF-triggered apoptosis in OV-90 cells, and TSRC1 overex-
pression has an opposite eﬀect on apoptosis.2. Materials and methods
2.1. Chemicals
Recombinant human TNF was kindly provided by Professor Shouy-
uan Zhao (Fudan University). Transcription inhibitor Actinomycin D
(AcD) was purchased from ALEXIS CORPORATION. When cells
were treated with TNF, AcD (0.2 lg/ml) supplemented to the medium
can inhibit the transcription activation of survival genes and block the
activation of NF-jB pathway mediated by TNF. Speciﬁc cathepsin B
(CTSB) inhibitor CA074Me and its substrate z-RR-AMC were from
BIOMOL, pan-caspases inhibitor zVAD-fmk was from CALBIO-
CHEM. The lysosomotropic ﬂuorochrome acridine orange (AO),
propidium iodide (PI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were from Sigma.
2.2. Plasmid construction and cell transfection
In the procedures of colocalization assay, coding sequence of cathep-
sin B was in-frame constructed into the ﬂuorescent protein expression
vector pDsRed-N1, and bikunin and TSRC1 were cloned into pEGFP-
N2 vector, respectively. Coding sequences of bikunin and TSRC1 were
cloned into vector pcDNA3.1-myc-HisA(), respectively, so as to
detect eﬀects of overexpression of bikunin or TSRC1 on OV-90 cells
apoptosis. Cells were transfected with above plasmids by means of
LipofectAMINE (Invitrogen).
2.3. Cell viability assay
104 Cells/well were seeded into a 96-well plate and grown overnight.
TNF was added at the given concentration and the indicated time
point, and cell survival was measured by MTT staining.
2.4. Lysosomal integrity assays
AO-relocation and AO-uptake methods described in detail in Ref.
[7] were used to analyze lysosomal integrity. In AO-relocation, cells
were ﬁrst exposed to an AO solution (5 lg /ml) in complete culture
medium for 15 min at 37 C and then rinsed and treated with TNF
for 4 h or 8 h. Green cytosolic ﬂuorescence of 10000 cells per sample
was measured by a ﬂow cytometry in the FL1 channel (FACScan; Bec-
ton Dickinson). In AO-uptake, cells were ﬁrst treated with TNF for 8 h
and then exposed to AO solution as described above. Red lysosomal
ﬂuorescence of 10000 cells per sample was measured by a ﬂow cytom-
etry in the FL3 channel.
2.5. PI-FACS analysis
Apoptosis was quantiﬁed on the basis of the amount of sub-G1-
DNA by a ﬂow cytometry as described in detail in Ref. [14].
2.6. Cathepsin B enzymatic assay
Cells were ﬁrst washed twice with PBS and then lysed. Cathepsin B
activity was estimated by adding 10 ll cell lysate and 50 lM z-RR-
AMC to cathepsin B reaction buﬀer (50 mM sodium acetate, 4 mM
EDTA, 8 mM DTT, 1 mM pefablock, pH 6.0). The release of 7-ami-
do-4-methylcoumarin (AMC) (excitation 365 nm, emission 440 nm)
was measured with a ﬂuorometer (Cary Eclipse Fluorescence Spectro-
photometer, VARIAN), and then normalized for the amount of pro-
tein [12]. Protein content was determined by Bradford assay (BioRad).
2.7. Yeast two-hybrid screening
Here used methods are described in detail in Ref. [15]. The open
reading frame of cathepsin B was fused to Gal4-BD domain on the
pGBKT7 vector as bait plasmid and human fetal liver cDNA library
was screened. The positive prey plasmids were rescued from yeast cells
and then sequenced. A mating test was performed to pluck the speciﬁc
protein–protein interactions.2.8. Glutathione S-transferase pull-down assay in vitro
Cathepsin B was cloned into the pGEX-5X-1 vector and expressed
in Escherichia coli strain BL21. Bikunin was cloned into pGBK7 vector
and the Myc-Bikunin fusion protein was generated by the TNT T7
Quick Coupled Transcription/Translation System (Promega). Gluta-
thione S-transferase (GST) pull-down assay was performed as de-
scribed in Ref. [15].
2.9. Coimmunoprecipitation assay in vivo
Coimmunoprecipitation assay was performed as described pre-
ciously [15]. Cathepsin B was constructed into vector pCMV-HA, bi-
kunin and TSRC1 were cloned into vector pCMV-Myc, respectively.
HeLa cells were cultivated in 6-well plates to 80% conﬂuence and then
co-transfected with pCMV-HA-CTSB and pCMV-MYC-Bikunin or
pCMV-MYC-TSRC1, respectively. After 48 h of incubation, cells were
collected and analyzed so as to detect the interaction between CTSB
and bikunin or TSRC1.3. Results
3.1. Cathepsin B is involved in TNF-induced demise of ovarian
cancer cells OV-90
Based on reports, the eﬀects of TNF treatment depend on
the cell types. Some cells are sensitive to TNF cytotoxicity after
inhibition of NF-jB pathway [2,3]. As shown in Fig. 1A, we
screened ovarian cancer cells OV-90, TOV-112 D, prostatic
cancer cells PC-3, hepatoma cells Hep3B and SMMC-7721
so as to determine their susceptivity to TNF cytotoxicity. We
found that all examined cancer cells were resistant to treatment
of TNF alone. However, when the transcription inhibitor acti-
nomycin D was supplemented to the medium, OV-90, PC-3
and SMMC-7721 cells were susceptible to TNF-induced death.
For OV-90 cells, its values of MTT assays decreased from
89.0% to 26.7%; for PC-3 cells, from 102.6% to 56.0%; for
SMMC-7721 cells, from 91.5% to 26.6%. Either speciﬁc
cathepsin B inhibitor CA074Me (25 lM) or pan-caspases
inhibitor zVAD-fmk (1 lM) could reduce the death of these
three TNF-sensitive cell lines (Table 1). Furthermore, the re-
sults of apoptosis detected by PI-FACS also showed that
25 lM CA074Me and 1 lM zVAD-fmk suppressed TNF-med-
iated OV-90 cells apoptosis from 23.9% to 15.9% and 12.6%,
respectively (Fig. 1B). Based on above experimental results,
it concludes that the cathepsin B and caspases are involved
in the OV-90 cells apoptosis induced by TNF.
3.2. TNF induces lysosomal rupture in OV-90 cells
Cathepsin B is experimentally testiﬁed to be involved in the
TNF-induced apoptosis of OV-90 cells, and this protease is lo-
cated in lysosomes. It is necessary to study stability of lyso-
somes during the cell apoptosis for the better understandings
of apoptosis mechanisms. The highly sensitive AO-relocation
method was used to detect release of AO from ruptured lyso-
somes to the cytosol. AO is a metachromatic ﬂuorophore that
shows strong red ﬂuorescence in lysosomes and weak green
ﬂuorescence in cytosol. As shown in Fig. 2A, an enhanced cel-
lular green ﬂuorescence, 113.5% compared with the control,
became detectable as early as 4 h after OV-90 cells were treated
with TNF/AcD, and then the ﬂuorescent intensity was in-
creased to 139.2% at 8 h. Results of the AO-uptake assay
showed an increased numbers of ‘‘pale cells’’, i.e., cells with re-
duced numbers of AO-accumulating lysosomes, after TNF-
treating 8 h, which also demonstrated lysosomal rupture
(Fig. 2B). Preincubation with either CA074Me or zVAD-fmk
Fig. 1. Sensitivity of human cancer cell lines to TNF treatment and
protective eﬀects of cathepsin B and caspases inhibitors on TNF/AcD-
induced apoptosis in OV-90 cells. (A) Ovarian cancer cells OV-90 and
TOV-112D, prostatic cancer cells PC-3, hepatoma cells Hep3B and
SMMC-7721 were screened for their susceptivity to TNF cytotoxicity.
The survival cells were measured by MTT assay after 22 h treatment
with TNF (1000 U/ml) and AcD (0.2 lg/ml) or TNF (1000 U/ml)
alone. (B) OV-90 cells were cotreated 16 h with TNF (1000 U/ml) and
AcD (0.2 lg/ml) after preincubation with cathepsin B speciﬁc inhibitor
CA074Me (25 lM) or pan-caspase inhibitor zVAD-fmk (1 lM) for 2 h
and the apoptosis of cells was analyzed by PI-FACS analysis. The
values are given as the percentage of apoptotic cells with sub-G1
chromosomal DNA content. All data represent means of at least
triplicate determinations ± S.D.
Fig. 2. (A) Early lysosomal rupture assayed with the AO-relocation
method. OV-90 cells were stained with AO, rinsed, and cotreated with
TNF (1000 U/ml) and AcD (0.2 lg/ml) for 4 h or 8 h. Increase in
green-AO ﬂuorescence, indicating release of AO from ruptured
lysosomes to the cytosol (10000 cells per sample), was measured by
ﬂow cytometry. The green-AO intensity of cells which were not treated
with TNF was as control. (B) Lysosomal rupture assayed with the AO-
uptake method. After preincubating with or without 25 lM CA074Me
(or 1 lM zVAD-fmk) for 2 h, OV-90 cells were treated with TNF/AcD
(same concentration as above indicated) for 8 h and then exposed to
AO. Intensity of lysosomal ﬂuorescence from 10000 cells per sample
was measured. Cells with decreased red ﬂuorescence (‘‘pale’’ cells) were
gated, and their percentages are indicated. Each data is an average of
triplicate samples.
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and 8.39%, respectively. And so it is inferred that the inhibition
of cathepsin B or caspases activity would enhance the lyso-
somal stability.
3.3. Cathepsin B speciﬁcally interacts with bikunin or TSRC1
To understanding the pathway of cathepsin B in the cell
death, the Clontech Matchmaker Two-Hybrid system 3 andTable 1
Eﬀects of cathepsin B and caspases inhibitors on the death of cancer cells tr
Cell line MTT conversion (%)
TNF TNF/AcD TNF/AcD +
OV-90 89.0 ± 1.6 26.7 ± 6.0 50.1 ± 9.7
PC-3 102.6 ± 4.8 56.0 ± 4.3 70.6 ± 7.3
SMMC-7721 91.5 ± 1.2 26.6 ± 5.4 41.4 ± 4.4
Cells were preincubated with CA074Me (25 lM) or zVAD-fmk (1 lM) for
survival cells were measured by MTT assay. Results represent means of tripthe yeast mating assay were used to screen and identiﬁed
cathepsin B interacting proteins. As a result, we found that bi-
kunin and TSRC1 interact with cathepsin B. Bikunin belongsiggered by TNF/AcD
CA TNF/AcD + zVAD TNF/AcD + CA + zVAD
67.6 ± 10.3 85.1 ± 4.1
71.8 ± 2.8 84.8 ± 3.2
48.4 ± 0.7 51.3 ± 2.6
2 h before a treatment with TNF/AcD as indicated in Fig. 1A. The
licate determinations ± S.D.
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novel protein and its function remains unknown. To conﬁrm
the interactions between cathepsin B and bikunin or TSRC1
observed in yeast two hybrid, the GST pull-down assay
in vitro and coimmunoprecipitation assay in vivo were per-
formed. It was testiﬁed that GST-CTSB conjugated on gluta-
thione-Sepharose 4B beads speciﬁcally pulled down bikunin
while GST alone did not (Fig. 3B). In the procedures of coim-
munoprecipitation assay, HeLa cells were cotransfected with
pCMV-Myc-CTSB and pCMV-HA-Bikunin or pCMV-HA-
TSRC1. Immunoblot analysis veriﬁed the eﬃcient expression
of CTSB, bikunin and TSRC1 in cell lysates (Fig. 3C). Mono-
clonal anti-Myc antibody and protein A/G-agarose were
added into the cell lysates so as to precipitate Myc-CTSB.
HA-Bikunin or HA-TSRC1 was speciﬁcally detected in the
precipitate by using anti-HA antibody as primary antibodyFig. 3. Validation of interaction of CTSB with bikunin and TSRC1.
(A) Expressed and puriﬁed GST and GST-CTSB proteins were
analyzed by SDS–PAGE. Lanes 1 and 3 represent total soluble
proteins of E. coli BL21 containing GST and GST-CTSB, respectively;
lanes 2 and 4 represent puriﬁed GST and GST-CTSB, respectively. (B)
The interaction of CTSB with bikunin was analyzed by GST pull-
down assay in vitro. GST-CTSB fusion protein immobilized on
glutathione-Sepharose 4B beads was incubated with Myc-Bikunin
translated in vitro. Binding proteins were immunoblotted with anti-
Myc primary antibody. Bikunin binds speciﬁcally to GST-CTSB, but
not to GST alone. The translation product of bikunin in vitro was used
as a positive control. (C) The speciﬁc interaction between CTSB and
bikunin (or TSRC1) was conﬁrmed by coimmunoprecipitation in vivo.
HeLa cells were cotransfected with pCMV-Myc-CTSB and pCMV-
HA-bikunin (or pCMV-HA-TSRC1) and the expressions of Myc-
CTSB, HA-Bikunin and HA-TSRC1 were analyzed by western
blotting with anti-Myc or anti-HA primary antibody, respectively.
The lysates from cotransfected cells were immunoprecipitated using
mouse anti-Myc antibody. The precipitated proteins were eluted from
the protein A/G PLUS agarose and analyzed by western blotting using
anti-HA primary antibody. HC and LC represent the heavy chain and
light chain of mouse IgG, respectively.(Fig. 3C). Both the results of in vitro and in vivo binding as-
says validate that CTSB interacts with bikunin or TSRC1.
CTSB fused with red ﬂuorescence protein RFP and bikunin
or TSRC1 with green ﬂuorescence protein GFP were coexpres-
sed in OV-90 cells. As shown in Fig. 4, Bikunin-GFP or
TSRC1-GFP was completely colocalized with CTSB-RFP in
cellular lysosomes, displaying spots-like ﬂuorescence as re-
ported in Ref. [16]. These results further support the fact that
CTSB interacts with bikunin or TSRC1.
3.4. Overexpression of bikunin or TSRC1 changes the sensitivity
of OV-90 cells to TNF-induced cell death
To investigate the functions of CTSB interacting proteins bi-
kunin and TSRC1, bikunin and TSRC1 were cloned into
expression vector pcDNA3.1/myc-HisA() and transfected
OV-90 cells, respectively. After 48 h of transfection, the cells
were treated with TNF/AcD and apoptosis of cells was mea-
sured. Bikunin and TSRC1 were overexpressed in cells as ex-
pected (Fig. 5B). TNF-induced apoptosis of OV-90 cells with
the overexpression of bikunin decreased from 31.8% to
19.5%, compared to that of control cells transfected with vain
vector; to the contrary, the apoptotic cells with TSRC1 overex-
pression increased to 59.6%, whereas apoptosis level of OV-90
cells was just 14.4% after preincubation of cathepsin B speciﬁc
inhibitor CA074Me (Fig. 5A). Based on the experimental data,
overexpression of CTSB interacting proteins bikunin or
TSRC1 is correlated with TNF-induced OV-90 cells apoptosis.
The bikunin overexpression suppresses apoptosis of OV-90
cells triggered by TNF, to the contrary, overexpression of
TSRC1 enhances cells apoptosis.
Eﬀects of overexpression of bikunin and TSRC1 on cellular
cathepsin B activity are investigated. As shown in Fig. 6, the
cellular CTSB activity in OV-90 cells with bikunin overexpres-
sion was 58%, compared with that of the control, however,
TSRC1 overexpression almost had no inﬂuence on cellular
CTSB activity. If OV-90 cells were pretreated for 2 h withFig. 4. Colocalization of CTSB with bikunin or TSRC1 in OV-90 cells.
(A) OV-90 cells were cotransfected with pDsRed-N1-CTSB and
pEGFP-N2-Bikunin. (B) OV-90 cells were cotransfected with pDs-
Red-N1-CTSB and pEGF-N2-TSRC1. After 48 h of cotransfection,
the cells were observed and captured with LEICA TCSNT ﬂuorescent
confocal microscope at 480 nm and 568 nm emission wavelengths,
respectively. Overlay images demonstrate that CTSB is colocalized
with bikunin or TSRC1 in cellular lysosomes.
Fig. 5. Inﬂuence of bikunin or TSRC1 overexpression in OV-90 cells
on TNF-induced apoptosis. Expression vectors containing cDNAs of
bikunin or TSRC1 were transfected into OV-90 cells. (A) At 48 h post-
transfection, cells were incubated with 1000 U/ml TNF + 0.2 lg/ml
AcD, CA074Me (25 lM) was added 2 h before treatment of TNF/
AcD. After 16 h of treatment, cells were harvested for PI-FACS
analysis. Each data is an average of triplicate samples. (B) Cell extracts
were analyzed for the expression of bikunin and TSRC1 by immuno-
blot.
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of the controls. Accordingly, bikunin might suppress TNF-
mediated apoptosis of OV-90 cells by inhibiting enzyme activity
of CTSB.Fig. 6. Eﬀect of bikunin or TSRC1 overexpression on cellular
cathepsin B activity in OV-90 cells. After 48 h of transfection as
mentioned in Fig. 5, cathepsin B activities of cell extracts were
measured. As a control, CA074Me was added in the culture medium
2 h before the harvest of cells. Each data is an average of triplicate
samples.4. Discussion
Based on recent ﬁndings, beside the traditional apoptotic
process mediated by caspases, the lysosomal cysteine prote-
ases cathepsins, most notably cathepsin B, also participate
in apoptotic signaling and they may function upstream or
downstream of caspases [6,9–12]. It is well established that
many human cancer cells express high level of cathepsins
and cytotoxity of TNF causes a variety of cells apoptosis
[2,3,17,18]. To this end, we screened several human cancer
cell lines for their sensitivity to cytotoxity of TNF. Also,
we further investigated the relations between cathepsin B
and TNF-triggered cell death. We ﬁnd that ovarian cancer
cells OV-90 is sensitive to the cytotoxity of TNF when the
cells were cotreated with transcription inhibitor actinomycin
D, and that the apoptosis triggered by TNF/AcD is not only
caspase-dependent but also cathepsin B-dependent (Fig. 1).
Cathepin B and caspases inhibitors can also protect PC-3
and SMMC-7721 cells from TNF-mediated cell death, indi-
cated in Table 1. And so, our research supports the view that
the cellular death responses depend on cell types.
A variety of lysosomal damaging agents or stimulus can re-
sult in destability of lysosomes with release of cathepsins to
cytosol, leading to apoptosis of cells [6–8]. As shown in
Fig. 2, our experiments demonstrate that lysosomes undergo
a permeabilization process in TNF-treated OV-90 cells, and
that inhibitors against caspases and cathepsin B protect lyso-
somes from rupture. And so the active caspases and cathepsin
B may cause lysosomal destabilization in OV-90 cells treated
by TNF. The mechanisms response for TNF-associated lyso-
somal break down remain unknown in many cases and these
questions need to be elucidated at molecular level.
A well accepted fact is that cathepsin B is a major mediator
of apoptosis pathway under many circumstances, however, lit-
tle is known about cellular inhibitors or activators to cathepsin
B. We try to ﬁnd those factors that interact with cathepsin B
and that may intervene cathepsin B-mediated death process.
Bikunin and TSRC1 are such two proteins interacting with
cathepsin B that we have identiﬁed by yeast two-hybrid meth-
od, and also we have conﬁrmed the interactions by binding as-
says and colocalization analysis.
TSRC1, an interaction partner of cathepsin B, has 424 ami-
no acids and 5 TSP1 (Thrombospondin type 1 repeats) do-
mains, but its function is unknown. Our study showed that
overexpression of TSRC1 enhances OV-90 cells apoptosis in-
duced by TNF, in the meantime, without inﬂuence on cellular
cathepsin B enzyme activity. It was reported that some TSP1
domain-containing proteins like Thrombospondin 1 and
Thrombospondin 2 could induce apoptosis of endothelial cells
[19,20], but it is not clear how these proteins work in death
pathway. Our results about TSRC1 provide some clues to fu-
ture investigation in this direction.
Bikunin, another partner of cathepsin B, has a kunitz-type
protease inhibitor with inhibitory activity against some prote-
ases such as trypsin, plasmin and granulocyte elactase [13].
Bikunin performs anti-metastatic functions against some can-
cer cells, but its mechanism remains unclear at present [21].
The bikunin protein is not expressed in normal ovary cells,
while ovarian cancer tissues from diﬀerent patients show wide
variability in the expression of bikunin. There is a signiﬁcant
correlation between low expression of bikunin and metastasis
of ovarian cancers, and exogenously added bikunin would
250 J. Liu et al. / FEBS Letters 580 (2006) 245–250reduce invasion and metastasis of ovarian cancer cells [22,23].
For the ﬁrst time, we verify that, ﬁrst of all, bikunin interacts
with cathepsin B speciﬁcally; secondly, overexpression of bi-
kunin protects ovarian cancer cells OV-90 from TNF-induced
apoptosis, concomitantly with decrease of cellular cathepsin
B activity. The results imply that bikunin may act as an
inhibitor against cathepsin B to protect cells from death.
Cathepsin B is associated with tumor invasion and metastasis
in many experimental and clinical cases, and evaluated as po-
tential diagnostic and prognostic markers for tumors [17,18].
The expression level of cathepsin B is upregulated in many
human cancers, such as breast cancer, lung cancer, brain can-
cer, colorectal cancer, head and neck cancer, and melanoma,
and it can be secreted from tumors and cancer cell lines.
Cathepsin B works as a cysteine protease to degrade extracel-
lular matrix proteins like collagen IV and lamin. It can acti-
vate the precursor form of urokinase-type plasminogen
activator (uPA), which is a well-known factor to initiate pro-
teolysis of extracellular matrix, and thus lead to cancer
growth and invasion. Studies also show that the expression
of cathepsin B is enhanced both in human ovarian cancer tis-
sue and in serum from patients. Furthermore, increase in
cathepsin B level corresponds to ovarian cancer development
[18]. All available data indicate that cathepsin B plays a crit-
ical role in malignant progression. Therefore, it is feasible
that bikunin prevents tumor progression partially by inhibit-
ing cathepsin B activity.
Lysosomal cathepsins, particularly cathepsin B, have been
testiﬁed to be involved in cell death pathways. They cannot
only act in concert with caspases, but also independently exe-
cute apoptotic function [6–12]. Currently, relations between
caspases and cathepsins are poorly understood, and the regu-
lation of cathepsins in cellular apoptosis pathways remains un-
clear. Cathepsin B has two opposing roles in malignancy, one
role is that its proapoptotic features can reduce malignancy;
while the other is that secreted cathepsin B protein enhance tu-
mor invasion and metastasis. It is important for successful
treatment of cancers to profoundly understand functions of
cathepsin B in apoptosis. Our initial results show that cathep-
sin B and its candidate regulators, bikunin and TSRC1, partic-
ipate in apoptosis pathway of OV-90 cells. Further deeper
research is ongoing.Acknowledgements: This work was supported by grants from the Na-
tional Natural Science Foundation of China (NSFC, 30570914) and
from CNHLPP (2004BA711A19).References
[1] Ghobrial, I.M., Witzig, T.E. and Adjei, A.A. (2005) Targeting
apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55,
178–194.
[2] Micheaul, O. and Tschopp, J. (2003) Induction of TNF receptor
I-mediated apoptosis via two sequential signaling complexes. Cell
114, 181–190.
[3] Varfolomeev, E.E. and Ashkenazi, A. (2004) Tumor necrosis
factor: an apoptosis JuNKie?. Cell 116, 491–497.[4] Leist, M. and Jaattela, M. (2001) Four deaths and a funeral: from
caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol. 2,
589–598.
[5] Turk, B., Turk, D. and Turk, V. (2000) Lysosomal cysteine
proteases: more than scavengers. Biochim. Biophys. Acta 1477,
98–111.
[6] Turk, B., Stoka, V., Rozman-Pungercar, J., Cirman, T., Droga-
Mazovec, G., Oresic, K. and Turk, V. (2002) Apoptotic pathways:
involvement of lysosomal proteases. Biol. Chem. 383, 1035–1044.
[7] Yuan, X.M., Li, W., Dalen, H., Lotem, J., Kama, R., Sachs, L.
and Brunk, U.T. (2002) Lysosomal destabilization in p53-induced
apoptosis. Proc. Natl. Acad. Sci. USA 99, 6286–6291.
[8] Broker, L.E., Huisman, C., Span, S.W., Rodriguez, J.A., Kruyt,
F.A.E. and Giaccone, G. (2004) Cathepsin B mediates caspase-
independent cell death induced by microtubule stabilizing agents
in non-small cell lung cancer cells. Cancer Res. 64, 27–30.
[9] Guicciardi, M.E., Miyoshi, H., Bronk, S.F. and Gores, G.J.
(2001) Cathepsin B knockout mice are resistant to tumor necrosis
factor-a-mediated hepatocyte apoptosis and liver injury. Am. J.
Pathol. 159, 2045–2054.
[10] Cuicciardi, M.E., Deussing, J. and Miyoshi, H., et al. (2000)
Cathepsin B contributes to TNF-a-mediated hepatocyte apopto-
sis by promoting mitochondrial release of cytochrome c. J. Clin.
Invest. 106, 1127–1137.
[11] Werneburg, N., Guicciardi, M.E., Yin, X.M. and Gores, G.J.
(2004) TNF-a-mediated lysosomal permeabilization is FAN and
caspase 8/Bid dependent. Am. J. Physiol. Gastrointest. Liver
Physiol. 287, G436–G443.
[12] Foghsgaard, L., Wissing, D., Mauch, D., Lademann, U., Bast-
holm, L., Boes, M., Elling, F., Leist, M. and Jaattela, M. (2001)
Cathepsin B acts as a dominant execution protease in tumor cell
apoptosis induced by tumor necrosis factor. J. Cell Biol. 153, 999–
1009.
[13] Fries, E. and Blom, A.M. (2000) Bikunin-not just a plasma
proteinase inhibitor. Inter. J. Biochem. Cell Biol. 32, 125–137.
[14] Mund, T., Gewies, A., Schoenfeld, N., Bauer, M.K. and Grimm,
S. (2003) Spike, a novel BH3-only protein, regulates apoptosis at
the endoplasmic reticulum. FASEB J. 17, 696–698.
[15] Ye, X.X., Lu, H., Yu, Y., Ding, N., Zhang, N.L., Huo, K.K.,
Wan, D.F., Li, Y.Y. and Gu, J.R. (2005) P5644 interacts with
phosphatidylinositol-4-phosphate adaptor protein-1 associated
protein-1. Mol. Cell. Biochem. 271, 151–158.
[16] Werneburg, N.W., Guicciardi, M.E., Bronk, S.F. and Gores, G.J.
(2002) Tumor necrosis factor-associated lysosomal permeabiliza-
tion is cathepsin B dependent. Am. J. Physiol. Gastrointest. Liver
Physiol. 283, G947–G956.
[17] Podgorski, I. and Sloane, B.F. (2003) Cathepsin B and its role(s)
in cancer progression. Biochem. Soc. Symp. 70, 263–276.
[18] Berdowska, I. (2004) Cysteine proteases as disease markers. Clin.
Chim. Acta 342, 41–69.
[19] Guo, N., Krutzsch, H.C., Inman, J.K. and Roberts, D.D. (1997)
Thrombospondin 1 and type I repeat peptides of thrombospondin
1 speciﬁcally induce apoptosis of endothelial cells. Cancer Res. 57,
1735–1742.
[20] Armstrong, L.C., Bjorkblom, B.K., Hankenson, D., Siadak,
A.W., Stiles, C.E. and Bornstein, P. (2002) Thrombospondin 2
inhibits microvascular endothelial cell proliferation by a caspase-
independent mechanism. Mol. Biol. Cell. 13, 1893–1905.
[21] Kobayashi, H., Suzuki, M., Hirashima, Y. and Terao, T. (2003)
The protease inhibitor bikunin, a novel anti-metastatic agent.
Biol. Chem. 384, 749–754.
[22] Tanaka, Y., Kobayashi, H., Suzuki, M., Kanayama, N., Suzuki,
M., Yamakawa, T., Morishita, H. and Terao, T. (2003) Reduced
bikunin gene expression as a factor of poor prognosis in ovarian
carcinoma. Cancer 98, 424–430.
[23] Tanaka, Y., Kobayashi, H., Suzuki, M., Kanayama, N., Suzuki,
M. and Terao, T. (2004) Upregulation of bikunin in tumor-
inﬁltrating macrophages as a factor of favorable prognosis in
ovarian cancer. Gynecol. Oncol. 94, 725–734.
